Institutional & Family Asset Management’s Krystal Biotech KRYS Stock Holding History

Institutional & Family Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$735	Buy	+4	New	+$672	﹤0.01%	672

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Institutional & Family Asset Management's KRYS Position: Q2 2024 in Review

Institutional & Family Asset Management opened a new position in Krystal Biotech (KRYS) in Q2 2024: 4 shares worth $735. The stake represents ﹤0.01% of the portfolio and ranks #672 among its holdings.

245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

Institutional & Family Asset Management held 4 shares of Krystal Biotech worth $735 as of Q2 2024.
Krystal Biotech was a new Institutional & Family Asset Management position in Q2 2024.
Krystal Biotech made up ﹤0.01% of Institutional & Family Asset Management's portfolio in Q2 2024, its #672 holding.
245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.